Stefan Quenneville's questions to Quipt Home Medical Corp (QIPT) leadership • Q3 2024
Question
Stefan Quenneville of Venton Financial questioned the operational impact of GLP-1 drugs, asking specifically if insurance payers are requiring patients to try CPAP therapy first before approving GLP-1s for off-label sleep apnea treatment due to the significant cost difference.
Answer
CEO Gregory Crawford responded that Quipt has not observed a trend of insurance companies mandating CPAP therapy prior to GLP-1 reimbursement. Instead, he highlighted recent data from a major device manufacturer showing that patients prescribed a GLP-1 are 10.7% more likely to start PAP therapy. Crawford suggested this indicates that GLP-1s are acting as a complementary tailwind, bringing more health-conscious individuals into the healthcare system to address all their conditions, including sleep apnea.